The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.

The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.

A 20-year review traces how immune checkpoint inhibitors became a cornerstone of lung cancer treatment.

A population-based study of 1102 Canadian children found infants with bone and soft tissue tumors had poorer survival, driven largely by treatment deaths.

Liver disease disparities tied to insurance and race spanned HCC surveillance, transplant listing, and drug access in data at The Liver Meeting 2026.

Most patients with CLL/SLL who discontinued a first-line BTK inhibitor did not start second-line therapy, and older age was linked to worse outcomes.

A study of 132 patients with AML given venetoclax-based therapy, 10 profiled by single-cell sequencing, linked immune features to treatment response.

This week in health equity and access: Medicaid cuts; mailed FIT outreach; EEOC pregnancy rules; GLP-1 Bridge access; and 2027 policy shifts.